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Abstract:  
By the age of 40, virtually all patients with DS have neuropathological changes 
characteristic of AD. The aim of our study was to  investigate whether the levels 
of superoxide dismutase enzymes (SOD), glutathione peroxidase (GPx), or their 
ratio could predict cognitive decline in people with Down Syndrome (DS) over a 
4-year period. 
Thirty-two adults with Down syndrome  participated in a longitudinal study with 
SOD and GPx assays at baseline. Informants rated their functional ability and 
memory function at baseline and at 4 years follow-up. The more able adults with 
DS also completed assessments of language skills and memory, at two different 
time points 4 years apart. 
Twenty-six individuals with DS completed assessments of memory (Modified 
Memory Object Task, MOMT), Adaptive behaviour (ABAS) and receptive 
vocabulary (British Picture vocabulary, BPVS) at both time-points. SOD 
positively correlated with change on the MOMT score (r = 0.578, p =0.015). 
There were no significant correlations between GPx level or SOD/GPx ratio and 
temporal changes in ABAS, BPVS or MOMT scores. 
Our results suggest that SOD predicts memory decline over time and  that these  
anti-oxidant enzymes could be a potential target for prevention of memory 
deterioration in adults with DS. Further research is required to test whether 
supplements which improve SOD function can also prevent cognitive decline. 
These findings may also have implications for prevention of cognitive decline in 
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other groups which are at high risk of developing dementia, such as adults with 
familial AD or mild cognitive impairment.  
 
244 words 
 
Key words: 
Down Syndrome, aging, Alzheimer Disease, memory, superoxide dismutase, 
oxidative stress.  
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1. Introduction 
 
Oxidative stress represents an imbalance between the production and 
manifestation of reactive oxygen species. In oxidative stress, the human body 
lacks the ability to readily detoxify the reactive intermediates and to successfully 
repair the resulting damage. Oxidative stress has been implicated in many 
diseases. Among these, the role of oxidative stress in the pathogenesis of both 
main forms of dementia, vascular and Alzheimer’s Disease (AD), is well 
documented [1,2]. In people with Down Syndrome (DS), the most common 
genetic cause of intellectual disability (ID), the prevalence of AD increases 
significantly with age. By the age of 40, virtually all patients with DS have 
neuropathological and neuro-imaging changes characteristic of AD [3, 4]. 
Superoxide dismutases are an important antioxidant defense in human cells 
exposed to oxygen, and consist of three forms: SOD1 is located in the cytoplasm, 
SOD2 in the mitochondria, and SOD3 is extracellular.  SOD1 and SOD3 contain 
copper and zinc, whereas SOD2 has manganese in its reactive centre. The genes 
for the enzymes are located on chromosomes 21, 6, and 4, respectively. As DS is 
caused by the partial or complete triplication of chromosome 21 and Cu/Zn 
superoxide dismutase (SOD1) is encoded by genes on the same chromosome, 
people with DS may present with SOD over expression. The role of SOD is to 
convert the superoxide radical to cytoxic hydrogen peroxide, which is further 
detoxified by glutathione peroxidase (GPx) or catalase. As a result of the over 
expression of SOD1 (a dosage-sensitive gene), there could be an imbalance of the 
ratio of anti-oxidant enzymes (SOD, GPx, catalase), which has been proposed to 
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result in oxidative damage [5]. Contrary to the prevailing hypothesis, Strydom et 
al. found that low SOD/GPx ratios were associated with worse cognitive ability in 
young adults with DS prior to the onset of dementia, which remained after 
controlling for confounders such as sex, age or nutritional supplements [6]. 
Our aim was to follow up all participants of the original study [6] after a 4-year 
period and to investigate whether the levels of SOD, GPx and their ratio 
predicted cognitive ability, particularly memory function,  over time. 
2. Materials and Methods 
2.1. Patient population, ethics and consent procedures 
The study was approved by the National NHS research ethics service. We 
approached all 32 individuals that were recruited at baseline in 2006 to gain 
consent to participate in the follow-up study. All potential participants received a 
detailed information pack about the study, which included a specially designed 
explanatory leaflet for participants with DS. Thereafter, consent was sought from 
participants with DS and their carers. We followed the Mental Capacity Act, UK 
(2005) and if participants did not have the capacity to consent for themselves, 
we gained consent from carers. Assessments took place in the participants’ home 
and were undertaken by the same researcher (PZ). 
  
2.2 SOD1/ GPx measurements 
During the original study, blood samples were obtained (before 12 am) for 
enzyme analysis (SOD and GPx). Blood was couriered to the laboratory at 
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ambient temperature and was processed on the same day for SOD analysis. 
Aliquots were frozen on arrival for batched GPx analsis.  
SOD was measured using two methods. Firstly, SOD1 activity level was measured 
using standard spectrophotometric methods – in summary, a cytosolic fraction 
from a neutrophil suspension was added to rhodamine-110-chloride reagent 
(Sigma 83695_Fluka) and 0.1% diolein followed by 0.1M HCl and placed in a 
Hitachi U-2010 spectrophotometer at wavelength 532nm. Readings were taken 
at 3 min intervals for at least 15 mins until linearity was established. Mean 
activity was calculted per 3 minutes, with a reference value of 240 to 410 units.  
Secondly, as an indication of overall intracellular SOD “function”, patient 
neutrophils were separated on a Histopaque (Sigma Chemical Co) density 
gradient and diluted with buffered saline to 106 cells per ml. Detection of SOD 
enzyme function was measured by means of rhodamine-110-chloride reagent 
(Sigma 83695_Fluka) based on how effectively the maximal production of 
superoxide by toxic stimulation of the neutrophils with diolein can be switched 
off (reduced) by an extract of a patient's packed cells (which contained SOD1 and 
SOD2); this has a normal range of 41–47%. Lower results are obtained in 
patients with poor SOD function.   
GPx activity was determined in red blood cells using the method of Paglia and 
Valentine based on the NADPH coupled reaction [7]. The reference interval for 
red cell GPx was 67–90 international units of activity per gram of haemoglobin. 
2.3. Psychometric assessments 
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The same psychometric assessments were used at baseline and follow-up four 
years later . Functional ability was determined with the Adaptive Behaviour 
Assessment Scale (ABAS), completed by carers [8]. The cognitive subscale of the 
Dementia Questionnaire for the Persons with Learning Disabilities (DLD) 
(formerly known as the DMR) [9], was also scored by carers to provide a proxy 
measure of memory function in all participants, including those adults with DS 
who were not able to complete assessments. The British Picture Vocabulary 
Scale II (BPVS II) [10] was used to provide a measure of the approximate 
developmental level of the participants, and to measure their vocabulary 
acquisition, an important facet of intelligence [11]. A Modified Object Memory 
Task (MOMT) was used as a directly assessed measure of delayed short-term 
memory. It was based on a version of the test which has been shown to yield 
delayed recall scores that are sensitive to memory decline due to dementia 
status, but not level of intellectual disability [12]. It was further simplified by 
reducing the number of objects to 6 objects presented in 2 trials before testing 
immediate recall followed by delayed recall of all 6 items after 5 minutes.  
2.5. Data analysis 
Data was coded and analysed with Statistical Package for the Social Sciences 
(SPSS) version 11[13]. The SOD/GPx activity ration was calculated from the 
logarithms of the activities because of the different orders of magnitude [14]. 
Correlations between the changes in psychometric and functional assessments 
scores (BPVS, ABAS, MOMT) were examined using Spearman’s correlations. 
Mann Whitney U tests were used to compare scores between groups. The 
significance level was set at 0.05. 
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3. Results 
3.1. Demographics 
Twenty-six out of 32 (81,3%) individuals with DS were followed up, ranging 
from 23 to 50 years of age (mean 36.65  7.05) at the time of their follow-up 
assessments. Two (6.3%) of the original participants refused to participate again, 
and four (12.5%) were lost to follow-up. 
Table 1 summarizes the demographic details the 26 participants who were 
followed up, and the 32 patients of the original cohort. No significant baseline 
differences were noticed between the original cohort and the follow-up group, 
i.e. no bias was introduced by the loss of 6 participants. 
[Table 1] 
Participants with thyroid dysfunction were all receiving treatment, and none had 
clinical features of thyroid disorder. Those with epilepsy were diagnosed during 
childhood, and were stable on treatment. None of the participants had any other 
major neurological disorders. Hearing and vision deﬁcits were not severe and 
did not prevent participation in any of the psychometric tests.  
 
3.2 Psychometric assessments 
Four of the 26 participants had severe ID and were unable to complete the BPVS 
II because they had very limited or no speech. Out of a possible 168, the raw 
score ranged between 26 and 115 with a mean score of 55.68  21.19, and scores 
were approximately normally distributed. The equivalent developmental age 
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range of the participants was 3.00 to 12.58 years of age. Those rated to have a 
mild intellectual disability (ID) had a mean developmental age of 7.45 years and 
those with moderate ID, 4.63 years.  
None of the four participants with severe ID were able to complete the modified 
memory object task (MOMT); range 2-6, mean 4.82 ( 1.05). However, this test 
demonstrated good correlation with carer ratings obtained from the DLD 
cognitive score (Spearman's Rho =  -0.552, p=0.008), which allowed carer-
ratings of memory functioning for all participants.  All participants had a DLD 
cognitive score, ranging from 0-38, mean 11.88  11.93, and scores were not 
normally distributed. 
All participants had ABAS scores (excluding work skills, since none of them was 
employed), which ranged from 31 to 565 (mean 317.85  133.48) with an 
approximate normal distribution. 
Changes in MOMT scores (score at follow up minus score at baseline) did not 
show a significant relationship with age (Spearman’s Rho -0.095, p=0.683), and 
there was no statistical difference (at the 0.05 level) between men and women, 
or between those taking any vitamin tablets and/or food supplements and those 
who were not (table 1). 
 
3.3. Enzyme assays 
SOD1 activity level measurements (obtained at baseline) was available for 18 
subjects with follow-up data and ranged between 30 and 590 enzyme units 
(mean 324.28  167.13), compared to a normal range of 240 to 410. Functional 
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SOD studies completed at baseline were available for 20 of the participants who 
completed cognitive assessments four years later. They showed a range of 32% 
to 54% inhibition (mean 40.70  6.28).  11 participants (55%) had values lower 
than 41%, which indicates poor functioning of SOD.  
Overall SOD function and SOD1 enzyme activity were highly correlated (r=0.791, 
p<0.001). Since there were more participants with SOD functional studies, this 
was used rather than SOD1 enzyme activity in primary analyses. SOD function 
did not correlate with age (r = -0.053; p = 0.824) and no significant difference 
was found between the 13 males and the 13 females (p = 0.322), or between 
those taking nutritional supplements (n = 8) or not n = 17; p = 0.210). 
With normal values between 67 and 90 units/g Hb, the observed GPx levels at 
baseline of the 20 participants who had blood test results and completed 
cognitive assessments at both time points were between 39 and 87, mean 65.65 
 15.14.  
3.4 Relationship between enzymes and cognitive ability changes 
Table 2 lists the correlations between changes over 4 years on tests of functional 
ability, memory or language ability (ABAS, MOMT, and BPVS) and levels of GPx, 
activity of SOD1 and SOD/GPx ratio. Overall SOD function (%) was positively 
correlated with change in the MOMT score (Spearman's Rho = 0.578, p =0.015) - 
better SOD function was correlated with better memory functioning over time. 
There was also a trend for a correlation between SOD function and change in the 
BPVS score (Spearman's Rho = 0.413, p =0.088). We proceeded with a post-hoc 
analysis to determine if those with SOD function below the reference range (i.e. < 
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41%) were more likely to have memory decline than those with SOD  in the 
normal range (41 % and above). There was a trend towards statistical 
significance (Mann-Whitney U = 16.5; p = 0.053). There were no significant 
correlations between GPx level or SOD/GPx ratio and temporal changes in ABAS, 
BPVS or MOMT scores. 
[Table 2] 
4. Discussion 
4.1. Findings 
Our main finding is that a decline in memory performance over 4 years in adults 
with DS was positively correlated with SOD function measured at baseline. This 
means that the better SOD enzymes are  functioning, the better the memory 
performance is over time.  
4.2. Implications 
In a recent meta-analysis it was shown that numerous chromosome 21 genes, 
including SOD1, have significant dosage effects (15), but the effect of dosage 
imbalance in people with DS at the molecular and phenotypical level remains 
unclear despite ongoing efforts to understand the genetics of DS.  
We have previously shown that the oxidative system is associated with cognitive 
functioning in adults with DS [6]. Our current study showed that better SOD 
functioning predicts better memory performance in aging adults with DS. 
However, although some adults with DS in our study had increased SOD1 
enzyme activity levels, a significant proportion had low levels, demonstrating 
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considerable variation in phenotype. Furthermore, overall SOD function was 
below the reference range in more than half of our participants. This is in 
contrast to the general expectation of increased SOD activity and function in DS. 
Several previous studies, particularly those in children, have shown increased 
SOD levels in DS [16], although other studies have shown normal or reduced 
levels [17]. Our results suggest that SOD expression varies considerably in adults 
with DS, and that those individuals with low levels of SOD are more susceptible 
to develop cognitive decline. The variation in SOD function in our study may be 
influenced by compensatory adjustments of SOD2 in response to SOD1 activity, 
but this is unlikely as SOD1 activity correlated well with overall SOD function 
suggesting that most of the variation was related to SOD1. SOD1 variation may 
be due to allelic variation in the gene on chromosome 21, its interaction with 
other genes in the rest of the genome, and the environment.   
There are several experimental studies which suggests the mechanisms 
underlying our findings. In a key recent study, researchers crossed TG2576 mice, 
which expresses the human amyloid precursor protein (hAPP), with mice 
deficient in SOD1 to generate a mouse model expressing amyloid precursor 
protein while underexpressing superoxide dismutase (hAPP/SOD1--) [18]. Using 
control mice expressing APP but which had either partial or full superoxide 
dismutase expression (hAPP/SOD1+- or hAPP/SOD1++), it was shown that SOD1 
deletion accelerated learning and memory deficits,  which was associated with 
increased amyloid plaque formation and increased oxidative damage to protein 
or DNA in brain tissues. SOD1 deletion also accelerated soluble amyloid β 
formation particularly in older hAPP/SOD1-- mice, and caused neuronal 
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dysfunction and increased Tau phosphorylation. Further support comes from 
cellular studies, including a study which has shown that introduction of SOD1 to 
cultured neurons reduced Amyloid-Beta induced toxicity [19].  
 
At least one study has shown that dementia in adults with DS is associated with 
lower levels of SOD1 [20]. Moreover, levels of SOD1 were significantly decreased 
in postmortem brain samples of human Alzheimer's disease patients compared 
to age-matched individuals without Alzheimer's disease [18]. In another human 
post-mortem study levels of oxidative markers including SOD1 was  significantly 
correlated with mini mental status examination scores in the frontal cortex of 
individuals with mild cognitive impairment or Alzheimer's disease [2].  
 
In summary, these studies suggest that high levels of superoxide dismutase may 
protect against some of the effects of APP triplication in Down's syndrome. This 
contrasts with the oft-quoted hypothesis that SOD1 overexpression in DS causes 
oxidative stress which excacerbates development of Alzheimer’s pathology. The 
Down Syndrome phenotype varies considerably on an individual level, and our 
study is the first to show that there is a direct relationship between peripheral 
levels of superoxide dismutase in living individuals and their memory function 
over time.  
There are several implications of our findings. Firstly, although the exact 
relationship of peripheral SOD levels  to central nervous system activity of SOD is 
unknown, our study suggests that peripheral superoxide dismutase 
measurement is a potential biomarker for cognitive decline in DS. This needs to 
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be explored in larger scale studies. Secondly, it suggests that improvement in 
SOD function may be a potential treatment option to prevent or reduce cognitive 
decline in people with DS. Several substances have been found to upregulate or 
improve SOD function. These include resveratrol [3,5,4V-trihydroxystilbene], a 
naturally occurring phytoalexin present in high concentration in skin of grapes 
and in red wine, which upregulates SOD1 and other anti-oxidant enzymes [21]. 
Trans resveratrol (T-RES) has been shown to be effective in preventing cognitive 
deficits as well as oxidative stress in rats [22]. In addition to this, there is also 
evidence that RES prevents Aβ οligomerization and attenuates cognitive 
deterioration in a mouse model of Alzheimer’s Disease [23].  Moreover, RES, as a 
Sirtuin 1 (SIRT1) activator, can protect from the deleterious effects triggered by 
oxidative stress, α-synuclein  or amyloid-β peptide [24]. Therefore, resveratrol 
could possibly play a multiple role in DS in addition to improving the functioning 
of SOD. Another possible treatment option is statins which, in addition to their 
beneficial lipid modulation exert a variety of several so-called “pleiotropic” 
actions. Among these, Rosuvastatin, the most recent agent of the class to be 
introduced, has been shown to have an upregulation effect on the anti-oxidant 
enzymes [25].  
Although oxidative stress has been suspected to be an important factor in DS, 
recent trials of anti-oxidants in infants did not result in improvements of 
cognitive functioning, neither did it prevent cognitive decline in older adults [26, 
27]. Our findings suggest that better SOD function protects against memory 
decline in DS. Improving  SOD enzyme functioning in individuals with DS 
therefore presents a new potential treatment strategy that can be tested in 
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randomised trials .  As DS is a paradigm for Alzheimer’s disease, there is also a 
possibility that SOD has a role in cognitive decline in other high risk groups such 
as people with familial AD or Mild Cognitive Impairment. This needs to be 
investigated.   
Lastly, the MOMT appears to be a sensitive measure of memory decline in adults 
with DS. Memory decline has been found to be an early sign of dementia in older 
adults with DS along with emotional instability and behavioural change, while 
activities of daily living, which are included in ABAS, can remain relatively intact 
in early stages of dementia [28].  
4.3. Strengths and limitations 
We undertook a prospective cohort study, in which we managed to follow up 
more than 80% of the initial study group over 4 years.  We have included 
participants with the full range of cognitive abilities associated with DS, and our 
sample is therefore representative of the wide variation in intellectual 
phenotype as well as of SOD enzyme variation in adults with DS. We established 
that the MOMT has good validity by demonstrating good correlation between 
informant rated memory scores (DLD) and memory tests scores (MOMT) 
completed with participants with sufficient verbal ability.  
We were not able to control for all possible confounders. For example, cognitive 
performance may be influenced by educational exposure, though in the UK all 
adults with DS have equal access to education. It is also possible that dietary 
intake of food with anti-oxidant properties varied across participants. In patients 
with mosaicism, SOD1 expression cannot be predicted. In our follow-up group 
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we had one case with mosaicism, and therefore we were not able to study the 
relationship between SOD levels and mosaicism in more detail. The study was 
powered to detect correlations of moderate strength and it is therefore possible 
to have missed more subtle relationships.  Lastly, age-dependent decline of SOD  
activity has been reported [29] as well as a possible relationship between SOD 
and circadian rhythm [30]. Our participants had a narrow age range, and we did 
not demonstrate a relationship between age and enzyme levels at baseline. As 
for the circadian rhythm, the blood samples were all collected in the first half of 
the day.  
 
4.4 . Conclusion 
We have shown for the first time that SOD functioning predicts memory 
functioning in adults with DS over time, which is in keeping with experimental 
evidence that has demonstrated the deleterious effects of  SOD deficiency in the 
presence of APP overexpression. Our findings suggest that enhancement of 
superoxide dismutase functioning is a potential target for prevention of memory 
decline and dementia in adults with DS, and may also have implications for the 
treatment of other patient groups, such as those with familial AD. However, our 
sample was relatively small, and our results need to be confirmed with a larger 
cohort.  Potential positive effects of nutritional supplements that improve SOD 
function could be tested in DS mouse models, in concert with double blinded 
randomized control trials in humans with DS in order to test whether these 
supplements help to prevent cognitive decline. 
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 Column A  
Follow-up 
(n=26) 
Column B 
Original 
(n=32) 
p 
Male sex (%) 50.0 56.3 0.792 
Age as at baseline (years, mean  SD) 32.46  7.24 32.59  6.78 0.943 
Ethnicity   0.884 
    White (%) 76.9 75.0  
    Asian (%) 11.5 9.4  
    Black (%) 11.5 15.6  
Hx of cardiovascular disorder (%) 19.2 21.8 0.805 
Hx of visual disorder (%) 61.5 53.1 0.520 
Hx of hearing disorder (%) 38.4 40.6 0.867 
Hx of thyroid disorder (%) 23.1 21.8 0.913 
Hx of epileptic disorder (%) 3.8 6.2 0.681 
Level of intellectual disability    0.912 
    Mild (%) 26.9 31.2  
    Moderate (%) 57.7 56.3  
    Severe (%) 15.4 12.5  
  
Table 1. Summary of the baseline characteristics of the follow-up (column A) and 
original (column B) cohort. Non-continuous variables are given as percentages. 
Continuous variables are presented as mean  SD. SD, standard deviation; Hx, 
history. 
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*Significant at 0.05 level 
 
Table 2. Correlations between changes (score at follow up minus score at baseline) in psychometric measures, and anti-oxidant 
enzymes.
  SOD function  SOD1 
enzyme 
units 
GPx  SOD1 function/ 
GPx 
Change in  
ABAS score 
Spearman’s Rho 0.040 -0.229 0.329 -0.248 
 p 0.868 0.361 0.157 0.292 
 N 20 18 20 20 
Change in  
BPVS  score 
Spearman’s Rho 0.413 0.325 0.227 -0.096 
 p 0.088 0.219 0.366 0.704 
 N 18 16 18 18 
Change in 
MOMT score  
Spearman’s Rho 0.578 0.348 0.187 0.148 
 p 0.015* 0.204 0.471 0.570 
 N 17 15 17 17 
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